secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001213900-24-069029
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron reports H1 2024 net loss down 27%; Lomecel-B gets RMAT/Fast Track for Alzheimer's
--------------------------------------------------------------------------------

- H1 2024 net loss $7.5M (down 27% YoY from $10.3M); revenue $1.0M (up 105% YoY from $0.5M).
- Cash $12.4M at June 30; July capital raises gross $15.3M (Registered Direct $9.0M, warrant exercises $6.3M); runway through Q4 2025.
- FDA granted RMAT and Fast Track for Lomecel-B in mild Alzheimer's after positive Phase 2a CLEAR MIND data at AAIC.
- Phase 2b HLHS trial (ELPIS II) at 70% enrollment; targeting completion by end of 2024.
- Launched CDMO business; expects $4-5M annual revenue once fully operational.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390024069029/0001213900-24-069029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390024069029/ea0211362-8k_longe.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-069029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer